172 related articles for article (PubMed ID: 38051586)
1. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Yomtoubian S; Ng I; Tiriac H; Lowy AM; Zou J; Engle DD
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38051586
[TBL] [Abstract][Full Text] [Related]
2. The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Zou J; Engle DD
bioRxiv; 2023 May; ():. PubMed ID: 36747742
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Zhang Y; Houchen CW; Li M
Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
[TBL] [Abstract][Full Text] [Related]
5. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
Hawkins HJ; Yacob BW; Brown ME; Goldstein BR; Arcaroli JJ; Bagby SM; Hartman SJ; Macbeth M; Goodspeed A; Danhorn T; Lentz RW; Lieu CH; Leal AD; Messersmith WA; Dempsey PJ; Pitts TM
PLoS One; 2024; 19(4):e0298808. PubMed ID: 38598488
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
7. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
10. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
11. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
[TBL] [Abstract][Full Text] [Related]
12. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
Choi D; Gonzalez-Suarez AM; Dumbrava MG; Medlyn M; de Hoyos-Vega JM; Cichocki F; Miller JS; Ding L; Zhu M; Stybayeva G; Gaspar-Maia A; Billadeau DD; Ma WW; Revzin A
Adv Sci (Weinh); 2024 Feb; 11(5):e2303088. PubMed ID: 38018486
[TBL] [Abstract][Full Text] [Related]
13. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
[TBL] [Abstract][Full Text] [Related]
14. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
15. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma.
Koikawa K; Ohuchida K; Ando Y; Kibe S; Nakayama H; Takesue S; Endo S; Abe T; Okumura T; Iwamoto C; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Nagai E; Mizumoto K; Hashizume M; Nakamura M
Cancer Lett; 2018 Jul; 425():65-77. PubMed ID: 29580808
[TBL] [Abstract][Full Text] [Related]
16. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
[TBL] [Abstract][Full Text] [Related]
17. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
18. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology.
Dantes Z; Yen HY; Pfarr N; Winter C; Steiger K; Muckenhuber A; Hennig A; Lange S; Engleitner T; Öllinger R; Maresch R; Orben F; Heid I; Kaissis G; Shi K; Topping G; Stögbauer F; Wirth M; Peschke K; Papargyriou A; Rezaee-Oghazi M; Feldmann K; Schäfer AP; Ranjan R; Lubeseder-Martellato C; Stange DE; Welsch T; Martignoni M; Ceyhan GO; Friess H; Herner A; Liotta L; Treiber M; von Figura G; Abdelhafez M; Klare P; Schlag C; Algül H; Siveke J; Braren R; Weirich G; Weichert W; Saur D; Rad R; Schmid RM; Schneider G; Reichert M
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32614802
[TBL] [Abstract][Full Text] [Related]
19. Organoid models for translational pancreatic cancer research.
Tiriac H; Plenker D; Baker LA; Tuveson DA
Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
[TBL] [Abstract][Full Text] [Related]
20. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
